Michael Taylor is a former racing driver from Great Britain. He participated in 2 Formula One World Championship Grands Prix, debuting on July 18, 1959. He scored no championship points. He also participated in several non-Championship Formula One races. His racing career effectively ended when his steering column weld failed on his Lotus 18 in the 1960 Belgian Grand Prix at 160 mph. He was thrown from the car, cutting down a tree with his body and broke several bones. He was paralysed, but due to therapy he is now on his feet. Because of his car failure Taylor later sued Lotus successfully, one of the few successful actions against the makers of a racing car. Taylor never raced again after his accident at Spa Francorchamps but turned instead to property speculation.
• Craig Packer (Dr. Craig Packer is an ecologist. His research interests include ecology of infectious diseases, ...)
• Saar Klein (Saar Klein is an American film editor who has been nominated twice for Academy Awards, and who re...)
• Adam Conover (Adam Conover is an American comedian, writer, and television host. He is the host of the half-hou...)
Seeking Alpha is a website where people from all over the world share their investing ideas.
I edit and curate Seeking Alpha's biotech/pharma coverage and I onboard new writers so they can share their investing ideas with Seeking Alpha's readers!
Let's talk stocks, investing, Seeking Alpha, online media, etc., etc.
EDIT: I'm done! Thanks very much for all your questions. This was a great experience. :)
Hi, Mike! Now that AVXL has run its course, what is the next great pump and dump opportunity? Cheers!
Without commenting specifically on the AVXL situation: Public biotech companies trade on hope and the promise of a substantial future payoff. It's precisely because the craziest ideas sometimes work that a lot of investors can get carried away by stories.
I don't think that small-cap biotech is for the faint of heart. It requires a lot of due diligence, and people get burned even when they're careful. My take: Acting on hot tips is always a bad idea, but especially dangerous in biotech.
If you could give some concise advice about writing a strong, thorough analysis of a biotech opportunity, what would it be?
I think a lot of writers can overlook company fundamentals because they're so focused on the science and the amazing opportunity for advancement. The problem is that the clinical stats can sometimes distract from what might make a company a good or bad opportunity from a business standpoint.
For evaluating clinical stage products, I'd say it's good to start with understanding the disease, or the problem being addressed, then evaluate the market size and level of competition. Ask yourself about the pros and cons of the product, then assess what management has to do to get there. It's absolutely critical to go beyond company-provided sources and to do thorough due diligence to create successful analysis. There are a lot of moving parts, and I think a person has to really study the industry before just diving in.
Finally, I prefer analysis that operates against the backdrop of the risk involved, especially for cash-burning bio/pharma companies that have a long way to go before they ever reach the market. Was that concise? The people will decide.
Hi Mike - Seeking Alpha is often described as favoring shorts over longs. An unusual comment from editor & CEO Eli Hoffman seems to have raised some eyebrows. Very strange comment for an editor of a publication to seemingly favor shorts over longs on this trade.
Eli Hoffmann, CEO , Contributor
"Took a while for this to play out. Hope some stuck with the short.
21 Jul, 02:51 "
The Pump Stopper
Author’s reply » thanks Eli,
Keubiko , Contributor
<-------- "stuck with the short.
And hats off to Pump Stopper."
Do you care to comment?
Hi 50billionStocks. That is an excellent question.
First of all, I think one of the things that distinguishes SA is that it publishes short ideas at all. (Also, our short ideas tend to get a lot of attention.) Publishing a meaningful volume of short ideas is not ultra common among financial media outlets, so it's easy to see why we'd get a reputation as being overly short-friendly just on that basis.
I personally don't think we are. Even taking a recently controversial stock like AVXL, one of our top contributors is bullish, and featured it prominently multiple times this week. Our mission is spirited discussion on all aspects of a given investment. That includes bearish takes.
I won't speak for Eli, he's more than capable of speaking for himself.
But I'll talk in general terms -- our editors form opinions about particular stocks. That's inevitable when your job is to evaluate the quality of multiple investment cases every day. Probably every editor publishes articles every day that he or she personally disagrees with.
I personally value investment commentary that presents useful information to the public and helps investors make better decisions. Long ideas and short ideas both can make that happen.
Do you think markets are efficient? If so, why do we have a ban on insider trading? Wouldn't it make more sense to permit insider trading as it would have information be reflected more quickly? Do you agree that insider trading bans really only serve high-speed traders?
I believe markets are efficient enough to make it very difficult for anyone to beat them over the long term.
My understanding from reading Matt Levine at Bloomberg is that insider trading is about theft of intellectual property and not fairness. If that's true, then strong-form market efficiency obviously doesn't hold. But I don't think even Harry Markowitz or John Bogle believe that.
I think allowing insider trading could create perverse incentives for company employees to use the company's information to benefit themselves in the stock market rather than their employers. There's probably more to consider than price discovery when you think about insider trading.
I don't agree that insider trading bans really only serve high-speed traders. Does anyone think that?
How many YOLOs does it take to hit it big in biotech investing?
5 million premoney YOLOs, 35 million YOLOs is pretty standard to get you through Phase 1-2.
From an investor's standpoint are Shkreli's actions as "evil" as the media has made them out to be? Is what he did a rather common practice, more so than what the general public is aware of?
This is an interesting question, lick. Seeking Alpha usually tries to keep the focus on the investment case. I think that actions in the past several years by numerous companies, Shkreli's Turing and RTRX before it included, have revealed that the system in the U.S. is vulnerable to abuse. It's a thorny issue when it's not always the patients who are paying directly for the drugs, and when big-payday incentives have driven so much innovation in the past few decades.
Amid the height of the Turing scandal, Evaluate Pharma created a list of companies that have raised prices in excess of 70%, sometimes at a compound rate over a number of years. Can't find the link at the moment, but it was a disappointingly long list. ... I'm not that deep in the drug-by-drug statistics, but it seems from a broad standpoint that some drugs are priced more appropriately than others, to put it mildly.
One last note on Shkreli: It seems to me he is willing to play the heel in this business. I don't admire him by any means, but let's at least admit he makes no pretense of respectability, and has revealed a real leak in our system. Hopefully he keeps backing down from Turing's original position.
How much have you made from insider trading? shorting stocks before an article is published. :)
I've never traded on material nonpublic information. In fact I've never traded. I don't even actively manage my investments. I invest in boring old index funds and am content to live off my wages as an editor. Thanks for the question, though, mangist.
Will I be able to turn $5k into $5M using your website?
First of all, love your site. It's on my daily list of reads especially for my portfolio, stocks I'm watching and macro news.
Hi programmingguy, thanks for the question. Glad you like the site.
Why does Seeking Alpha's mobile site push the app so hard that I won't even read it on my phone?
Not speaking for the company, I agree with you that this creates a pain point for readers -- I've felt it myself. My impression is that it's hard to get people downloading and using apps, but that good ones create a user experience that's sticky and beneficial for both the reader and the company. Again not speaking for the company, I expect that Seeking Alpha will swing between ends of this trade-off over time -- sometimes gating the browser site on mobile devices to get people using the app, sometimes being more accommodating of browser-based use of the site from mobile. Good question, and thanks for giving us feedback on this.
How do you determine the criteria for a good pharma or biotech stock? It seems as if their development cycles can take decades. How do you know if what they're developing is relevant in the future? How do you factor in FDA approval processes when evaluating the stock as well? In general, how risky are pharma or biotech stocks?
I have a hard time mentally endorsing any clinical stage biotech stocks. I personally like when companies have assets and revenue to provide some kind of backstop for an investor, and that's not typically available in the industry except among well-established megacaps.
If I were more speculative-minded, I'd be looking for products that address pressing unmet needs. I'd also be rigorously checking management's use of the cash made available to them. Great scientists don't always make great businesspeople, so I'd be quick to sell at the first sign that a company wasn't executing on its plan.
The FDA is tricky. I have been memorably wrong about at least two major approval decisions in the past year. There is fierce ongoing debate about what clinical markers the FDA is likely to accept in cancer, for example. It seems like it's very rare for a bio/pharma company to produce data that's an obvious layup for approval.
Pharma and biotech stocks are ultra-risky. They are often made of cash and an idea. Investors can easily hurt themselves. Scientific data create a particularly dangerous type of confirmation bias. And even if you understand a product, that's only half the story at most. Management has to correctly structure and properly execute clinical trials, then develop a reasonable go-to-market plan. There's probably a dozen layers of uncertainty added on to the typical stock-market risk you'd find investing in a grocery store or what have you.
If you don't see any reason to sell $AVXL now you must see promise in the rest of there pipeline. Despite the low chances of drugs that target these difficult to target deseases making it to the average joe do you see promise in all of there upcoming drugs? When do you think $AVXL might add a new drug to there pipeline?
Hi realerlifethrowaway. For starters: I am not sure I said any of the things you're mentioning. I don't have a scientific view on $AVXL, because I am not an expert in Alzheimer's and haven't done any specific research on their products. The science is unclear to me, and I suspect it's unclear even to management at this early stage in the process.
I have no better guess about the chances of success than anyone else in this case, or in many other cases. More than 0%, less than 100%? If you have a view I hope you'll share it. Likewise about any new pipeline drugs.
Hi Mike! I know because I used to work with you that you left journalism, got a business degree, worked in the business world for a bit, and then came back to journalism with Seeking Alpha. How did that trajectory influence you as an editor? Should more journalists think about getting an MBA?
PS Should more MBAs think about getting into journalism? Or is that crazy?
This might sound bad, but I became much more interested in investments and finance through business school. It's something you have to work at to understand, and you have to understand it to find it engaging. So business school helped me engage in the investing world in a new way by tuning me into the positive and negative implications of public companies' actions. It also alerted me to how many stories go untold in the business press. So business school was energizing from a journalism standpoint.
Not necessarily getting MBAs, but more business journalists should learn more about business. There can be a tendency, especially in New York, to defer to experts and industry professionals, especially when looking for quotes. With the proper training, journalists are much better off doing their own homework and analysis.
More MBAs should think about getting into journalism. But they'd probably be taking pay cuts. Maybe after their first big exit. :)
What do you like best about being Seeking Alpha's biotech editor?
I like the constant flow of ideas, and the capacity the stock market has to surprise me. I've thought to myself that quite a few stocks were totally dead in the water only to see an acquisition or trial result completely turn things around. Most of all I admire the panache and rigor our best contributors bring to their coverage.
Would you advise the folks who lost thousands and thousands of dollars on AVXL to visit /r/investing and index, or visit /r/wallstreetbets and keep the YOLO alive?
Thanks for another question, lick. Academic research shows that naively giving equal weight to a bunch of different strategies is a successful approach to investing for retirement. I believe in allocating to different levels of risk based on the level of need for the asset. So your emergency funds should be in cash or close, retirement assets should be conservative. You should keep the YOLO alive with some money after thorough fundamental analysis, but only do max YOLO top-down 90 mph speculating with money you would otherwise be happy setting on fire.
As a teenager, what can I do to get into investing?
Read financial publications like (plug) Seeking Alpha, The Wall Street Journal, The Economist. Take business-related classes, and save up for college. Build savings so that when you have some ideas worth acting on you have some money to put to work. None of this is personalized investment advice!
Recently, you wrote an article about "Average PE Ratio" being a bad metric, is there an Average PE Ratio for an index above which you would not invest? (E.g., I wouldn't invest in any S&P 500 stock if the indices average PE ratio were above 30 because I would think there would be a massive downturn coming and I wouldn't be confident enough that I could pick winners.) If so, what is that PE ratio for you? The article is at: http://seekingalpha.com/instablog/19888591-sa-editor-mike-taylor/4513976-why-average-pe-ratio-can-be-a-dangerous-valuation-tool
I don't think PE tells the whole story of a company. My disposition doesn't tend toward growth investing, so super high PE ratios aren't attractive to me. When looking at a company I'm not usually looking at PE in isolation. Sorry to be boring with my answer. How about 10. 10 starts to feel comfortable, margin of safety wise.
With the understanding that you are not providing investment advice (and that you are essentially acting as Jim Cramer), if you were able to invest in only one publicly traded bio-tech company, which would it be and why? (And at the outset, would you view the purchase as a long-term or short-term buy?)
The closest I've come is I told an old business school classmate I was really looking carefully at Gilead Sciences sometime in the past few years. That story hasn't changed very much. Check out Seeking Alpha's coverage of the company. It's a mysterious one from a valuation perspective. Not investment advice, and I have no positions in individual stocks.
Isn't crowdsourcing just a way to get money without working for it, and without any oversight or expectations that it is anything but a way to support someone who couldn't make it on their own and probably shouldn't be funded in the first place?
You could view it that way, though Seeking Alpha pays its contributors, so I think there's a clear exchange of value right there, and if you asked me what I do from 8 a.m. to 5 p.m. every day, one answer I personally would give is "working for money."
It sounds like the second part of your question is referring to crowdfunding? Maybe you can clarify.
Mike, how do you value biotechs which are in the middle of their life cycle? That is, that are already profitable and cash flows and such...?
That's a tough one. I don't have a systematic answer. The big thing for companies with approved products is how long the products are likely to maintain share and pricing power. That's a really hard thing to forecast. It's made more difficult by my perception that "mid-stage" companies as you call them don't seem to last long as independent entities -- either spiraling out or getting acquired.
Do you think Herbalife is a pyramid?
I'll let the lawyers fight out the answer to your question. But I'm glad I can make a living doing something besides selling shakes, which seems like quite a grind.
Do you know or follow Greg Mannarino? Why was he kicked off seaking alpha? What are your thoughts on his bearish view of global markets?
I don't know or follow him, sorry. I like bearish takes because they make people second-guess their assumptions, and they're usually more entertaining to read.
What are the most common reasons articles don't get published by SA?
How often do editors fact check data or information shared in articles?
Would you say most articles you come across are repetitive or refreshing?
The most common reasons articles don't get published on SA are:
1) Outside the scope -- we get a fair amount of wealth management and personal finance content, which is a little broad for what we're targeting. We're looking for specific and actionable ideas on stocks and ETFs that trade on U.S. exchanges. We get a lot of well-written articles that just don't quite fall in line with our mission.
2) Underdeveloped/not forward-looking. We want articles that can help investors make decisions, so we wind up giving a lot of feedback about articles that are more recaps of the current situation than opinion pieces that can inform investors.
The company's position as I understand it is: We're a platform so we don't endorse the factual assertions of articles. This is why we often publish completely opposing viewpoints on the same company. We make sure the information is clear and gives readers an idea of the evidence supporting it to the best of our ability. When a material fact is disputed with legitimate supporting evidence, we make a correction or, in rare cases, will retract an article.
Being honest, I get a fair share of articles that seem repetitious from my perspective, but I read a lot of what comes across the transom, so I might not be a fair judge. We want to create a place where people can discuss ideas, and sometimes the insight comes from the discussion threads in the comments. I tend to err on the side of publishing when articles are repetitious, but it's a judgment call.
Do you read zerohedge.com? If so, what are your thoughts on it?
I used to read it a lot, in 2008-2010. I like bearish takes and the overall style of the site. I don't think I can really use much of the content to make investment decisions, but the attitude is fun.
If you were addressing an audience of SA authors, what would be one thing you'd say we're doing well at, and one thing we need to work on?
Do you think the current US funding/pricing model for new drugs is sustainable? How could it be improved?
This is a great question. One thing I think we as editors need to do better at is going beyond enforcing our minimum standards and start providing authors with material that gives them opportunities to learn and grow as analysts.
I think my broad feedback for authors would be the flip side of that: Authors have the tendency to get into a groove with their approach, and I think over time there can be a tendency to stop trying to refine the analysis, look for new types of opportunities and approaches, that kind of think. I'd exhort authors to always be trying to learn something new, identify and challenge their own assumptions, and get increasingly specific with their data and evidence. The most exciting authors are the ones who manage to make large leaps in the level of their analysis over time. I'd encourage all authors to keep that goal in mind.
I think that there is potential for more on than saber-rattling around specialty pharmacies when it comes to regulation. It's a complex issue, but I think the downstream system looks a little dysfunctional at the moment. By the same token, an exceptional drug development industry is a key competitive advantage for the US economy, and it seems like regulators understand that profit incentives are a key part of that. Overall I think IP protection for novel compounds will continue to be an important source of big competitive advantages for drug developers -- the core of the system is likely to remain intact.
Why should I listen to what Seeking Alpha says more than the experts at /r/wallstreetbets?
An investor should listen to a variety of sources, but there's probably no substitute for doing one's own diligence and making decisions according to what one knows about his or her asset base and risk tolerance. Not individual investment advice.
If you like /r/wallstreetbets, that's great.
Will Star Wars blow up DIS like I think it will?
Star Wars will blow up the Death Star and probably do very little to DIS stock price of any immediate consequence.